+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Vascular Dementias Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768196
  • Report
  • April 2019
  • Region: Global
  • 61 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • A2 Healthcare Corp
  • Abbott Laboratories
  • Eisai Co Ltd
  • Glovia Co ltd
  • Johnson & Johnson
  • Novartis AG
  • MORE
The global clinical trial report- “2019 Vascular Dementias Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Vascular Dementias. It presents in-depth analysis of Vascular Dementias clinical trials across markets and companies. The research work is for providing complete understanding into trends in Vascular Dementias.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Vascular Dementias clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Vascular Dementias

The research work is prepared through extensive and continuous research on Vascular Dementias trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Vascular Dementias patients are identified
  • The report includes panorama of Vascular Dementias clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Vascular Dementias clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • A2 Healthcare Corp
  • Abbott Laboratories
  • Eisai Co Ltd
  • Glovia Co ltd
  • Johnson & Johnson
  • Novartis AG
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Vascular Dementias Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Vascular Dementias Clinical Trials by Region
2.2.2 Average Enrollment of Vascular Dementias Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Vascular Dementias Treatment, 2019

3. Region wise Vascular Dementias Clinical Trials
3.1 Asia Pacific Vascular Dementias Clinical Trials by Country
3.2 Europe Vascular Dementias Clinical Trials by Country
3.3 North America Vascular Dementias Clinical Trials by Country
3.4 Middle East and Africa Vascular Dementias Clinical Trials by Country
3.5 South and Central America Vascular Dementias Clinical Trials by Country

4. Vascular Dementias Clinical Trial Trends
4.1 Start Year wise Vascular Dementias Clinical Trials
4.2 Phase wise Vascular Dementias Clinical Trials
4.3 Trial Status wise Vascular Dementias Clinical Trials
4.4 Trial Type wise Vascular Dementias Clinical Trials

5. Vascular Dementias Average Enrollment Trends
5.1 Average Enrollment in Vascular Dementias Trials by Year
5.2 Average Enrollment in Vascular Dementias Trials by Phase
5.3 Average Enrollment in Vascular Dementias Trials by Status
5.4 Average Enrollment in Vascular Dementias Trials by Type of Trial

6. Companies Participating in Vascular Dementias Clinical Trials
6.1 Vascular Dementias Trials by Sponsor Type
6.2 Vascular Dementias Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Vascular Dementias Trials- Phase 1
7.2 Vascular Dementias Trials- Phase 2
7.3 Vascular Dementias Trials- Phase 3
7.4 Vascular Dementias Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Vascular Dementias Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Vascular Dementias Clinical Trials and Enrolment
Figure 5: Europe - Country wise Vascular Dementias Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Vascular Dementias Clinical Trials and Enrolment
Figure 7: North America - Country wise Vascular Dementias Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Vascular Dementias Clinical Trials and Enrolment
Figure 9: Vascular Dementias Clinical Trials by Phase
Figure 10: Vascular Dementias Clinical Trials by Trial Status
Figure 11: Vascular Dementias Clinical Trials by Type
Figure 12: Vascular Dementias Clinical Trials by Sponsor Type
Figure 13: Vascular Dementias Clinical Trials by Leading Sponsors
Figure 14: Vascular Dementias Average Enrollment by Phase
Figure 15: Vascular Dementias Average Enrollment by Trial Status
Figure 16: Vascular Dementias Average Enrollment by Type
Figure 17: Vascular Dementias- Average Enrolment by Type of Sponsors
Figure 18: Vascular Dementias- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Vascular Dementias Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Vascular Dementias Clinical Trials and Enrolment
Table 5: Europe - Country wise Vascular Dementias Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Vascular Dementias Clinical Trials and Enrolment
Table 7: North America - Country wise Vascular Dementias Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Vascular Dementias Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Vascular Dementias Average Enrollment by Phase
Table 15: Vascular Dementias Average Enrollment by Trial Status
Table 16: Vascular Dementias Average Enrollment by Type
Table 17: Vascular Dementias- Average Enrolment by Type of Sponsors
Table 18: Vascular Dementias- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • A2 Healthcare Corp
  • Abbott Laboratories
  • Charsire Biotechnology Corp
  • Dr. Willmar Schwabe GmbH & Co KG
  • Eisai Co Ltd
  • Glovia Co ltd
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc
  • Shionogi & Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll